Nuveen LLC Invests $441,000 in Fulcrum Therapeutics, Inc. $FULC

Key Points

• Nuveen LLC has made a new investment of approximately $441,000 in Fulcrum Therapeutics, acquiring 152,992 shares, which brings its total ownership to about 0.28% of the company.
• Several institutional investors, including Suvretta Capital Management and Woodline Partners, significantly increased their stakes in Fulcrum, highlighting growing confidence in the company.
• Analysts have issued mixed ratings for Fulcrum Therapeutics, with price targets ranging from $5.00 to $12.00, reflecting varying outlooks on the stock's performance in the near term.

Nuveen LLC bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 152,992 shares of the company's stock, valued at approximately $441,000. Nuveen LLC owned approximately 0.28% of Fulcrum Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in FULC. Suvretta Capital Management LLC lifted its position in Fulcrum Therapeutics by 182.3% during the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock valued at $15,691,000 after buying an additional 2,155,675 shares during the period. Woodline Partners LP grew its position in shares of Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after buying an additional 739,713 shares during the period. LMR Partners LLP grew its position in shares of Fulcrum Therapeutics by 367.2% in the 4th quarter. LMR Partners LLP now owns 112,500 shares of the company's stock worth $529,000 after buying an additional 154,600 shares during the period. Northern Trust Corp grew its position in shares of Fulcrum Therapeutics by 25.1% in the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company's stock worth $3,339,000 after buying an additional 142,578 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $658,000. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded up $0.78 during trading hours on Friday, hitting $7.66. The company's stock had a trading volume of 599,040 shares, compared to its average volume of 381,469. Fulcrum Therapeutics, Inc. has a 12 month low of $2.32 and a 12 month high of $9.30. The company's 50 day simple moving average is $7.06 and its two-hundred day simple moving average is $5.48. The company has a market cap of $414.34 million, a P/E ratio of -6.28 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. As a group, research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research report on Thursday, May 15th. Piper Sandler restated an "overweight" rating and set a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Royal Bank Of Canada raised their price target on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a report on Wednesday, July 30th. HC Wainwright upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $4.00 to $12.00 in a report on Tuesday, July 29th. Finally, Leerink Partners upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the company from $4.00 to $12.00 in a report on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.57.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.